FDA Tells Baxter To Tone Down Aralast Claims
The U.S. Food and Drug Administration has issued a warning letter chastising Baxter International Inc. for overstating the effectiveness of Aralast, a lung therapy for patients at risk for a form...To view the full article, register now.
Already a subscriber? Click here to view full article